Inhibition of stemness and EMT by taxifolin ruthenium-p-cymene complex via downregulating the SOX2 and OCT4 expression on lung cancer

被引:5
作者
Das, Abhijit [1 ]
Ghosh, Balaram [2 ]
Dasgupta, Sandipan [3 ]
Seal, Ishita [1 ]
Sil, Sidhanta [1 ]
Roy, Souvik [1 ]
机构
[1] NSHM Knowledge Campus Kolkata, Dept Pharm, 124 BL Saha Rd, Kolkata 700053, West Bengal, India
[2] Midnapur Med Coll, Dept Pharmacol, Midnapore, West Bengal, India
[3] Maulana Abul Kalam Azad Univ Technol, Dept Pharmaceut Technol, Nadia 741249, West Bengal, India
关键词
Taxifolin; Ruthenium-p-cymene; Stemness; Epithelial-to-mesenchymal transition; Lung cancer; EPITHELIAL-MESENCHYMAL TRANSITION; PI3K/AKT/MTOR PATHWAY INHIBITORS; KI-67; EXPRESSION; PHENOLIC CONTENT; BETA-CATENIN; IN-VITRO; ANTIOXIDANT; APOPTOSIS; GROWTH; THERAPY;
D O I
10.1016/j.arabjc.2023.104995
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
Lung carcinoma is perhaps the most often reported cancer incidence throughout the world. The flavonoid metal complexes have exhibited a potential chemotherapeutic effect. This study investigated the chemotherapeutic effect of taxifolin ruthenium-p-cymene complex against lung carcinoma through MTT assay, transwell migration assay, sphere formation assay, western blot, histopathology, immunohistochemistry, and TUNEL assay. The in silico study determined the target proteins of the complex. The synthesized organometallic complex was characterized via various spectroscopical techniques. The complex exhibited strong binding affinity for PI3K, EGFR, and 0-catenin. The complex promoted apoptosis and inhibited the colony formation of the cancer cells. Moreover, the cancer cell migration and cancer stemness were reduced with decreased SOX2 and OCT4 expression. The complex induced cell cycle arrest at sub G0/G1 phase, S phase and G2/M phase and promoted caspase-3 mediated apoptosis. The in vivo study demon-strated successful restoration of lung tissue due to the treatment with the complex in benzo-a-pyrene induced lung cancer model. Additionally, the expression of p53 and caspase-3 was increased with significant downregulation of Akt, mTOR and 0-catenin. In conclusion, the complex inhibited can-cer cell viability, stemness, and EMT in both in vitro and in vivo model systems through the alteration of PI3K/Akt/mTOR/EGFR pathway and expression of stem cell markers including SOX2 and OCT4 that eventually abrogated the EMT mediated metastasis of cancer cells. (c) 2023 Published by Elsevier B.V. on behalf of King Saud University.
引用
收藏
页数:22
相关论文
共 38 条
[1]  
Allardyce CS, 2001, PLATIN MET REV, V45, P62
[2]   Elevated Ki-67 expression is correlated with TNFα- and IFNγ-induced apoptosis in tumour cells [J].
Baisch, H .
CELL PROLIFERATION, 2002, 35 (06) :333-342
[3]   The ferric reducing ability of plasma (FRAP) as a measure of ''antioxidant power'': The FRAP assay [J].
Benzie, IFF ;
Strain, JJ .
ANALYTICAL BIOCHEMISTRY, 1996, 239 (01) :70-76
[4]   Ruthenium(II) Arene Anticancer Complexes with Redox-Active Diamine Ligands [J].
Bugarcic, Tijana ;
Habtemariam, Abraha ;
Deeth, Robert J. ;
Fabbiani, Francesca P. A. ;
Parsons, Simon ;
Sadler, Peter J. .
INORGANIC CHEMISTRY, 2009, 48 (19) :9444-9453
[5]   The role of natural product chemistry in drug discovery.(vol 67, pg 2142, 2004) [J].
Butler, MS .
JOURNAL OF NATURAL PRODUCTS, 2006, 69 (01) :172-172
[6]   Wnt/β-catenin signaling in development and disease [J].
Clevers, Hans .
CELL, 2006, 127 (03) :469-480
[7]   Flavonoid-Modified Surfaces: Multifunctional Bioactive Biomaterials with Osteopromotive, Anti-Inflammatory, and Anti-Fibrotic Potential [J].
Cordoba, Alba ;
Satue, Maria ;
Gomez-Florit, Manuel ;
Hierro-Oliva, Margarita ;
Petzold, Christiane ;
Lyngstadaas, Staale P. ;
Luisa Gonzalez-Martin, Maria ;
Monjo, Marta ;
Ramis, Joana M. .
ADVANCED HEALTHCARE MATERIALS, 2015, 4 (04) :540-549
[8]   ANALYSIS OF TUMOR GROWTH CURVES [J].
DETHLEFSEN, LA ;
PREWITT, JMS ;
MENDELSOHN, ML .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1968, 40 (02) :389-+
[9]   Systematic design of a targeted organometallic antitumor drug in pre-clinical development [J].
Dyson, Paul J. .
CHIMIA, 2007, 61 (11) :698-703
[10]   Preclinical Rationale for PI3K/Akt/mTOR Pathway Inhibitors as Therapy for Epidermal Growth Factor Receptor Inhibitor-Resistant Non-Small-Cell Lung Cancer [J].
Gadgeel, Shirish M. ;
Wozniak, Antoinette .
CLINICAL LUNG CANCER, 2013, 14 (04) :322-332